Functional bowel disorders and functional abdominal pain, Gut, vol.45, issue.Supplement 2, pp.43-50, 1999. ,
DOI : 10.1136/gut.45.2008.ii43
Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQOL), Gastroent??rologie Clinique et Biologique, vol.30, issue.2, pp.241-247, 2006. ,
DOI : 10.1016/S0399-8320(06)73160-8
Rectal distention testing in patients with irritable bowel syndrome: Sensitivity, specificity, and predictive values of pain sensory thresholds, Gastroenterology, vol.122, issue.7, pp.1771-1778, 2002. ,
DOI : 10.1053/gast.2002.33601
Irritable bowel syndrome: a paroxysmal motor disorder, Lancet, vol.1, pp.620-621, 1986. ,
Dysmotility of the small intestine in irritable bowel syndrome., Gut, vol.29, issue.9, pp.1236-1279, 1988. ,
DOI : 10.1136/gut.29.9.1236
Ambulatory small intestinal motility in 'diarrhoea' predominant irritable bowel syndrome., Gut, vol.35, issue.2, pp.203-213, 1994. ,
DOI : 10.1136/gut.35.2.203
Altered small bowel motility in irritable bowel syndrome is correlated with symptoms, Gastroenterology, vol.92, issue.6, pp.1885-93, 1987. ,
DOI : 10.1016/0016-5085(87)90620-2
Disturbances in large bowel motility, Best Practice & Research Clinical Gastroenterology, vol.13, issue.3, pp.397-413, 1999. ,
DOI : 10.1053/bega.1999.0035
Abnormal REM sleep in the irritable bowel syndrome, Gastroenterology, vol.103, issue.1, pp.12-19, 1992. ,
DOI : 10.1016/0016-5085(92)91089-M
Alterations of sensori-motor functions of the digestive tract in the pathophysiology of irritable bowel syndrome, Best Practice & Research Clinical Gastroenterology, vol.18, issue.4, pp.747-71, 2004. ,
DOI : 10.1016/j.bpg.2004.06.004
Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome Committee for Proprietary Medicinal Products (CPMP). Points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome, Aliment Pharmacol Ther, vol.18, issue.12, pp.569-80, 2003. ,
Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials, The American Journal of Medicine, vol.107, issue.5, pp.91-98, 1999. ,
DOI : 10.1016/S0002-9343(99)00086-8
Outpatient treatment of neurotic depression: medication and group psychotherapy, Evaluation of the psychological therapies ,
Treatment of irritable bowel syndrome: a review of randomised controlled trials, Gut, vol.48, issue.2, pp.272-82, 2001. ,
DOI : 10.1136/gut.48.2.272
Irritable bowel syndrome symptom patterns: frequency, duration, and severity, Digestive Diseases and Sciences, vol.43, issue.12, pp.2715-2723, 1998. ,
DOI : 10.1023/A:1026663613695
Characterization of the Alternating Bowel Habit Subtype in Patients with Irritable Bowel Syndrome, The American Journal of Gastroenterology, vol.109, issue.4, pp.896-904, 2005. ,
DOI : 10.1046/j.1365-2036.2001.01010.x
Management of the irritable bowel syndrome, Gastroenterology, vol.120, issue.3, pp.652-68, 2001. ,
DOI : 10.1053/gast.2001.21908
Design of treatment trials for functional gastrointestinal disorders, Gut, vol.45, issue.Supplement 2 ,
DOI : 10.1136/gut.45.2008.ii69
Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome, Alimentary Pharmacology & Therapeutics, vol.33, issue.5, pp.499-510, 1994. ,
DOI : 10.1111/j.1365-2036.1994.tb00322.x
Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome, Alimentary Pharmacology and Therapeutics, vol.45, issue.3, pp.355-61, 2001. ,
DOI : 10.1016/0197-2456(86)90046-2
Pharmacologic Treatment of the Irritable Bowel Syndrome, Annals of Internal Medicine, vol.133, issue.2, pp.136-183, 2000. ,
DOI : 10.7326/0003-4819-133-2-200007180-00013
Discrepancies between Patient-Reported Outcomes and Clinician-Reported Outcomes in Chronic Venous Disease, Irritable Bowel Syndrome, and Peripheral Arterial Occlusive Disease, Value in Health, vol.9, issue.1, pp.39-46, 2006. ,
DOI : 10.1111/j.1524-4733.2006.00079.x
A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome, Alimentary Pharmacology and Therapeutics, vol.38, issue.1, pp.23-34, 2000. ,
DOI : 10.1046/j.1365-2036.1999.00610.x
Defining the predictors of the placebo response in irritable bowel syndrome, Clinical Gastroenterology and Hepatology, vol.3, issue.3, pp.237-284, 2005. ,
DOI : 10.1016/S1542-3565(04)00626-3
The placebo effect in irritable bowel syndrome trials: a meta-analysis, Neurogastroenterol Motil, vol.17, pp.332-372, 2005. ,
Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome, EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT), pp.669-81, 2005. ,
Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria, Gastroenterol Clin Biol, vol.28, pp.554-61, 2004. ,
Irritable bowel syndrome in ,
URL : https://hal.archives-ouvertes.fr/inserm-00410559
a common, debilitating and costly disorder, Eur J Gastroenterol Hepatol, vol.16, pp.995-1001, 2004. ,